A vaccine decision follows African outbreak research

At the gathering, WHO discussed African institutions evaluating safety and quality of traditional treatments.

The WHO account notes research on traditional remedies proposed for malaria, diabetes and other conditions; it does not establish efficacy.

The 2019 national commemoration put research, practitioners and public health in conversation.

The vaccine met WHO standards for quality, safety and efficacy for procurement by health agencies.

Prequalification helped pave the way for vaccine access in countries at risk of outbreaks.

The 12 November decision facilitated access but did not mean Ebola risk was gone.

The released genetic information enabled laboratories in many countries to begin developing diagnostic tests.

The newly available sequence let international teams compare the virus with other coronaviruses.

Public sequence data supplied a basis for molecular assays; validation and distribution followed later.

The dated release concerns genetic information, not a claim that vaccines or treatments were already available.